Valuation as at 2026-08-14 · see also the S&P 500 Most Undervalued screen
About Pfizer, Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
Source: Yahoo Finance company profile · factual description, not KashVector commentary
Pfizer, Inc. PFE
Healthcare · Drug Manufacturers - General
Pfizer, Inc.'s price & financial trends
Each card is labelled with its own reporting period — quarterly where Yahoo provides it for this market, annual otherwise.
Data as at 2026-08-14
Share price · last 2 years
Earnings per share (diluted) Per quarter
Free cash flow Per quarter
Dividend per share Per quarter
Value investing scale · Buffett · Dalio · Graham
1 criterion had no data
Intrinsic value estimate · 5-year forecast
Assumptions used in this valuation
Every input below is either fetched live from Yahoo Finance or a documented default — nothing is hidden.
| Bear | Base | Bull | |
|---|---|---|---|
| 5-yr FCF growth | 1.3% | 2.6% | 3.9% |
| Terminal growth | 2.5% | 2.5% | 2.5% |
| WACC (discount rate) | 6.68% | 5.68% | 4.68% |
Cost of Equity = Risk-free rate + Beta × Equity Risk Premium = 4.68% + 0.28 × 5.50% = 6.22% · WACC = weighted by 71%/29% capital structure
These numbers come from running Pfizer, Inc.'s cash flows through the mechanical DCF formula and assumptions above — not from any view on the news, management, or PFE's competitive position. What is DCF?
Want to test your own growth or discount-rate assumptions?Open the full interactive calculator, pre-filled with PFE →
More S&P 500 stocks we've valued
Not financial advice. DCF valuations are highly sensitive to assumptions — small changes in growth rate or discount rate produce large swings in output. This is a mechanical calculation, not a recommendation to buy, hold, or sell.
About this valuation
Computed on 2026-08-14 from Yahoo Finance data, using the same engine as the full DCF tool and the S&P 500 Most Undervalued screen. Every figure above is a point-in-time snapshot of that date — change any assumption yourself in the interactive tool for a live one.
Frequently asked questions
Is Pfizer, Inc. (PFE) undervalued?
The Base-case DCF estimates intrinsic value at $61.71 vs a price of $26.80 on 2026-08-14 — a +130.2% margin, so the Base case reads undervalued. This is a mechanical output, not advice.